We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Body Protection Compound 15-mer
Lyochem analytical fit
This Lyochem page is intentionally scoped to research-standard and analytical qualification work. The page should help a lab decide whether the BPC-157 lot is suitable for sequence verification, method development, stability pulls, and reference-material comparison. It is scoped to research qualification rather than regulated pharmacy procurement or release-packet sourcing.
Overview
BPC-157 is a 15-residue partial sequence (GEPPPGKPADDAGLV) of a protective protein first characterized in human gastric juice, and its proline-dense composition confers marked resistance to gastric and serum proteases. That stability underlies its use across tissue-repair models spanning tendon and ligament healing, gastrointestinal mucosal protection, endothelial and vascular repair, and post-injury bone metabolism. The peptide has drawn regulatory attention (notably the July 2026 FDA Pharmacy Compounding Advisory Committee agenda), but for laboratory buyers the operative questions remain chemical purity, confirmed sequence, and lyophilate stability rather than any compounding pathway. Lyochem supplies BPC-157 acetate as a lyophilized reference standard at ≥99.0% HPLC. The short chain synthesizes reliably by SPPS, yet closely eluting truncation impurities demand rigorous purification, so each lot carries peak-integrated RP-HPLC and ESI-MS agreeing within 0.5 Da of the theoretical 1419.55 g/mol. LC-MS/MS sequence confirmation (complete b-/y-ion ladder) is offered on request and is our recommended first qualification test for a new source, since mass alone establishes composition while tandem MS directly proves the synthesized sequence against the label. BPC-157 also anchors the Wolverine Blend (with TB-500) and GLOW Blend formulations; although BPC-157 (proline-rich gastric-protective peptide) and TB-500 (actin-binding 43-mer) are mechanistically unrelated, the Wolverine Blend SKU provides their canonical 1:1 co-lyophilate, with full composition stated on the COA.
Applications & buyer fit
Repair peptides — BPC-157, TB-500, B7-33, PEG-MGF — ship primarily to research labs studying tissue-repair, gastrointestinal-mucosa, tendon-ligament, and vascular-endothelial models. The synthesis itself is reliable, but analytical confirmation is where suppliers differ: buyers qualifying a new source should request sequence verification by tandem MS on the first lot and compare against the labelled sequence directly.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Lyochem supplies BPC-157 strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
Selected literature
Frequently asked questions
BPC-157 is a 15-residue peptide, and its proline-rich stretch does not change how it is characterized analytically. RP-HPLC with UV detection reports chemical purity and resolves the target from deletion or truncation impurities, ESI-MS confirms the intact mass, and LC-MS/MS sequence verification reads the b- and y-ion ladder to confirm the residue order. Sequence-level confirmation matters because mass alone can be ambiguous among short peptides, so requesting explicit sequence data on the batch COA is the reliable way to establish that the supplied material is BPC-157 and not a near-mass variant.
BPC-157 is commonly supplied as the acetate salt, and the salt form is part of accurate characterization because it affects both RP-HPLC retention and the mass balance of the vial. The acetate form elutes slightly earlier than free base under typical reverse-phase conditions, so retention should be interpreted against the stated salt. For dosing, the COA should report net peptide content after subtracting counter-ion and Karl Fischer water from the fill weight, since biological activity tracks actual peptide mass. Specifying free base versus acetate at quote stage ensures the reference data and the delivered form match your downstream work.